ReviewWorld journal of gastroenterology2014
Clinical approaches to non-alcoholic fatty liver disease.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?
Non-Alcoholic Fatty Liver Disease Patient Registry
Tocotrienol Against the Progression of End Stage Liver Disease
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- The effects of medicinal and food homologous substances on blood lipid and blood glucose levels and liver function in patients with nonalcoholic fatty liver disease: a systematic review of randomized controlled trials.Lipids in health and disease · 2023Pooled it
- The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial.International journal of molecular sciences · 2026Trial
- Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Trial
- Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.Obesity surgery · 2017Trial
- Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.World journal of gastroenterology · 2017Trial
- Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.Clinical immunology (Orlando, Fla.) · 2015Trial
- Article
- Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.Canadian liver journal · 2024Article
- Beneficial Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease (NAFLD) Progression in the Zebrafish Model.Nutrients · 2023Article
- Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study.International journal of environmental research and public health · 2022Observational
- Oral Administration of Recombinant Lactoferrin-Expressing Probiotics Ameliorates Diet-Induced Lipid Accumulation and Inflammation in Non-Alcoholic Fatty Liver Disease in Mice.Microorganisms · 2022Article
- The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery.Eating and weight disorders : EWD · 2022Article
- Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Iron Deficiency in Obesity and after Bariatric Surgery.Biomolecules · 2021Review
- Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease.Oxidative medicine and cellular longevity · 2021Article
- Therapeutic approaches for non-alcoholic steatohepatitis.Therapeutic advances in endocrinology and metabolism · 2021Article
- The Effects ofClinical nutrition research · 2021Article
- Honeybee Pollen Extracts Reduce Oxidative Stress and Steatosis in Hepatic Cells.Molecules (Basel, Switzerland) · 2020Article
- Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.Cureus · 2020Review
- Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin.International urology and nephrology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), leading to fibrosis and potentially cirrhosis, and it is one of the most common causes of liver disease worldwide. NAFLD is associated with other medical conditions such as metabolic syndrome, obesity, cardiovascular disease and diabetes. NASH can only be diagnosed through liver biopsy, but noninvasive techniques have been developed to identify patients who are most likely to have NASH or fibrosis, reducing the need for liver biopsy and risk to patients. Disease progression varies between individuals and is linked to a number of risk factors. Mechanisms involved in the pathogenesis are associated with diet and lifestyle, influx of free fatty acids to the liver from adipose tissue due to insulin resistance, hepatic oxidative stress, cytokines production, reduced very low-density lipoprotein secretion and intestinal microbiome. Weight loss through improved diet and increased physical activity has been the cornerstone therapy of NAFLD. Recent therapies such as pioglitazone and vitamin E have been shown to be beneficial. Omega 3 polyunsaturated fatty acids and statins may offer additional benefits. Bariatric surgery should be considered in morbidly obese patients. More research is needed to assess the impact of these treatments on a long-term basis. The objective of this article is to briefly review the diagnosis, management and treatment of this disease in order to aid clinicians in managing these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.